SCHEMBL2074450

SCHEMBL2074450

CCN1CCN(c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 16/20 0.51
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HDAC3 O15379 1/20 0.49
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
EGFR P00533 1/20 0.48
ERBB3 P21860 1/20 0.48
KIT P10721 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2075678 0.89 MAPK1 (0.53) MAPK1RAB9AALDH1A1SMN1; SMN2EGFR
SCHEMBL2076560 0.85 KIT (0.56) RAB9AALDH1A1SMN1; SMN2HDAC3ABL1
SCHEMBL2073186 0.82 KIT (0.51) RAB9AALDH1A1SMN1; SMN2HDAC3ABL1
SCHEMBL2076559 0.82 RAB9A (0.51) MAPK1RAB9AALDH1A1SMN1; SMN2HDAC3
SCHEMBL2072611 0.81 SMN1; SMN2 (0.73) MAPK1RAB9AALDH1A1SMN1; SMN2HDAC3
SCHEMBL2072590 0.76 RAB9A (0.54) RAB9AALDH1A1SMN1; SMN2EGFRERBB3
SCHEMBL2075547 0.75 RAB9A (0.50) MAPK1RAB9AALDH1A1SMN1; SMN2EGFR
SCHEMBL2074482 0.73 KIT (0.46) RAB9AALDH1A1SMN1; SMN2HDAC3ABL1
SCHEMBL2074683 0.73 RAB9A (0.73) MAPK1RAB9AALDH1A1SMN1; SMN2EGFR
SCHEMBL2072482 0.73 KIT (0.48) MAPK1SMN1; SMN2HDAC3ABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902184-B2 Piperazinyl pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2011-03-08 US disclosed
CN-101448820-A Piperidinyl pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2009-06-03 CN disclosed
EP-2032554-A1 PIPERIDINYL PYRIMIDINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-03-11 EP disclosed
WO-2007137955-A1 PIPERIDINYL PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-12-06 WO disclosed
US-20070281921-A1 Piperidinyl pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281921-A1 Piperidinyl pyrimidine derivatives HRH2, P2RX5, P2RX3 MAPK1 2242/4885RAB9A 1046/4885ALDH1A1 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.